EXHIBIT 99.1


                                 [COMPANY LOGO]



FOR IMMEDIATE RELEASE

CONTACT:   JOSEPH T. SCHEPERS

           VICE PRESIDENT, CORPORATE COMMUNICATIONS
           (770) 419-3355



                CRYOLIFE APPOINTS GERALD B. SEERY VICE PRESIDENT

                           OF INTERNATIONAL OPERATIONS

ATLANTA, GEORGIA... (JULY 7, 2005)... CRYOLIFE, INC. (NYSE: CRY), a biomaterials
and biosurgical  device  company,  announced today that Gerald B. Seery has been
appointed  to the newly  created  position of Vice  President  of  International
Operations.  Mr. Seery has been President of CryoLife Europa,  based in the U.K.
for the past three years,  and has  returned to the  corporate  headquarters  in
Kennesaw,  Georgia.  Mr.  Seery  joined  CryoLife  in 1993 and has held  several
positions with the Company  including  Marketing  Manager for vascular  tissues,
Director of  Marketing,  Vice  President  of  Marketing,  and  President  of the
Aurazyme subsidiary.  He is a graduate of The Catholic University of America and
has an MBA from Columbia University. Mr. Seery will continue to report to Steven
G. Anderson, President and CEO of CryoLife, Inc.

Steven G. Anderson,  President and CEO of CryoLife, Inc. stated, "One of the key
areas of opportunity and growth for the Company is our  international  business.
CryoLife's  international BioGlue(R) sales increased 27% in the first quarter of
2005 compared to the first quarter of 2004.  Approximately  22% of BioGlue sales
are  derived  outside  the  U.S.  The  consolidation  of all  of  the  Company's
international  operations  under  Gerry  Seery's  leadership  will  enable us to
increase our efforts to develop and  introduce  products in  geographic  regions
outside of the U.S."

The Company  markets the Model #100  SynerGraft  AV access  device,  the O'Brien
stentless  porcine heart valve and BioGlue  surgical  adhesive in  international
markets at this time.  The  Company  markets  and  distributes  its  products in
approximately  60 countries  throughout  the world.  The Company  also  recently
announced  its research  collaboration  with The Magdi  Yacoub  Institute at The
Imperial   College   in  London,   U.K.   to   improve   xenografts   for  human
transplantation.





ABOUT CRYOLIFE
Founded in 1984,  CryoLife,  Inc. is a leader in the processing and distribution
of  implantable  living  human  tissues for use in  cardiovascular  and vascular
surgeries  throughout  the  United  States and  Canada.  The  Company's  BioGlue
Surgical  Adhesive is FDA  approved as an adjunct to sutures and staples for use
in adult  patients in open surgical  repair of large vessels and is CE marked in
the European  Community and approved in Canada for use in soft tissue repair and
approved in Australia for use in vascular and pulmonary sealing and repair.

For  additional  information  about  the  company,  visit  CryoLife's  web site:
http://www.cryolife.com

                                       END